U.S. Markets closed

  • S&P Futures

    3,654.75
    +31.50 (+0.87%)
     

  • Dow Futures

    29,871.00
    +242.00 (+0.82%)
     

  • Nasdaq Futures

    12,383.25
    +106.25 (+0.87%)
     

  • Russell 2000 Futures

    1,841.60
    +21.50 (+1.18%)
     

  • Crude Oil

    44.94
    -0.40 (-0.88%)
     

  • Gold

    1,786.50
    +5.60 (+0.31%)
     

  • Silver

    22.93
    +0.34 (+1.51%)
     

  • EUR/USD

    1.1962
    +0.0027 (+0.23%)
     

  • 10-Yr Bond

    0.8440
    +0.0020 (+0.24%)
     

  • Vix

    20.57
    -0.27 (-1.30%)
     

  • GBP/USD

    1.3358
    +0.0026 (+0.20%)
     

  • USD/JPY

    104.3600
    +0.0360 (+0.03%)
     

  • BTC-USD

    19,592.22
    +82.34 (+0.42%)
     

  • CMC Crypto 200

    384.40
    +19.80 (+5.43%)
     

  • FTSE 100

    6,266.19
    -101.39 (-1.59%)
     

  • Nikkei 225

    26,824.46
    +390.84 (+1.48%)
     

Amphastar Pharmaceuticals Inc (AMPH) CEO & Chief Scientific Officer Jack Y. Zhang Sold $6. ...

GuruFocus.com

CEO & Chief Scientific Officer of Amphastar Pharmaceuticals Inc (30-Year Financial, Insider Trades) Jack Y. Zhang (insider trades) sold 300,000 shares of AMPH on 09/11/2019 at an average price of $20.82 a share. The total sale was $6.2 million.


Amphastar Pharmaceuticals Inc is a specialty pharmaceutical company engaged in developing, manufacturing, marketing and selling generic and proprietary injectable & inhalation products. Its products are used in hospitals or urgent care clinical settings. Amphastar Pharmaceuticals Inc has a market cap of $1.02 billion; its shares were traded at around $21.62 with a P/E ratio of 20.21 and P/S ratio of 3.29. GuruFocus has detected 1 severe warning sign with Amphastar Pharmaceuticals Inc. .

CEO Recent Trades:

  • CEO & Chief Scientific Officer, 10% Owner Jack Y. Zhang sold 300,000 shares of AMPH stock on 09/11/2019 at the average price of $20.82. The price of the stock has increased by 3.84% since.

CFO Recent Trades:

  • CFO, SVP & Treasurer William J Peters sold 4,942 shares of AMPH stock on 08/15/2019 at the average price of $21. The price of the stock has increased by 2.95% since.

Directors and Officers Recent Trades:

  • SVP Corp Admin Center Yakob Liawatidewi sold 3,910 shares of AMPH stock on 09/06/2019 at the average price of $21.65. The price of the stock has decreased by 0.14% since.

  • Director Richard K Prins sold 7,500 shares of AMPH stock on 08/26/2019 at the average price of $22.59. The price of the stock has decreased by 4.29% since.

For the complete insider trading history of AMPH, click here

.This article first appeared on GuruFocus.


Latest Stories

  • China Stocks Delisting Threat Grows For Alibaba, JD.com, Nio Amid House Vote, Kandi Fraud Allegations

    The House will vote this week on the Holding Foreign Companies Accountable Act. Will it lead to the delisting of Alibaba stock and other China stocks?

  • 2 Big Dividend Stocks Yielding 10%; Raymond James Says ‘Buy’

    Dividend stocks are the Swiss army knives of the stock market.When dividend stocks go up, you make money. When they don’t go up — you still make money (from the dividend). Heck, even when a dividend stock goes down in price, it’s not all bad news, because the dividend yield (the absolute dividend amount, divided by the stock price) gets richer the more the stock falls in price.Knowing all this, wouldn’t you like to find great dividend stocks? Of course you would. Raymond James analysts have chimed in – and they are recommending two high-yield dividend stocks for investors looking to find protection for their portfolio. These are stocks with a specific set of clear attributes: a dividend yield of 10% and Strong Buy ratings.Kimbell Royalty Partners (KRP)We’ll start with Kimbell Royalty Partners, a land investment company operating in some of the US’ major oil and gas producing regions: the Bakken of North Dakota, Pennsylvania’s Appalachian region, the Colorado Rockies, and several formations in Texas. Kimbell owns mineral rights in more than 13 million acres across these regions, and collects royalties from over 95,000 active wells. Over 40,000 of those wells are in the Permian Basin of Texas, the famous oil formation that has, in the past decade, helped turn the US from a net importer of hydrocarbons to a net exporter.The coronavirus crisis hit Kimbell directly in the pocketbook, knocking down share prices and earnings as economic restrictions, social lockdowns, and the economic downturn all struck at production and demand. The situation has only begun to revive, with the Q3 revenues growing 44% sequentially to reach $24.3 million.Kimbell has long been a reliable dividend payer, with a twist. Where most dividend stocks keep their payouts stable, typically making just adjustment in a year, Kimbell has a history of reevaluating its dividend payment every quarter. The result is a dividend that is rarely predictable – but is always affordable for the company. The last declaration, for the third quarter, was 19 cents per common share, or up 46% from the previous quarter. At that rate, the dividend yields ~10%,Covering the stock for Raymond James, analyst John Freeman noted, “Despite a strong quarterly performance and a nearly 50% distribution raise in 3Q, the market continues to under appreciate the unique value proposition of Kimbell's assets, in our view. Kimbell has a best-in-class 13% base decline, exposure to every major basin and commodity, as well as a very manageable leverage profile…”Regarding the possible anti-hydrocarbon stance of a Biden Administration, Freeman sees little reason for worry, saying, “Investors concerned about a potential Biden presidency (which appears increasingly likely) have little to fear in KRP. The company has less than ~2% of acreage on federal lands, meaning a frac ban on those properties would not have a material impact on KRP's business and might actually help them if it improved the overall supply impact."In line with these comments, Freeman rates KRP a Strong Buy, and his $9 price target implies it has room for 25% growth going forward. (To watch Freeman’s track record, click here)Wall Street appears to agree with Freeman, and the analyst consensus view is also a Strong Buy, based on 5 unanimous positive reviews. This stock is priced at $7.21, and its $11 average target is even more bullish than Freemans, suggesting a one-year upside of ~52%. (See KRP stock analysis on TipRanks)NexPoint Real Estate Finance (NREF)NexPoint inhabits the real estate trust niche, investing in mortgage loans on rental units, both single- and multi-family occupancy, along with self-storage units and office spaces. The company operates in the US, across major metropolitan hubs.NexPoint held its IPO in February this year, just before the coronavirus pandemic inspired an economic crisis. The offering saw 5 million shares sell, and brought in some $95 million in capital. Since then, the shares are down 13%. Earnings, however, have posted gains in each full quarter that the company has reported as a public entity, coming in at 37 cents per share in Q2 and 52 cents in Q3. The Q3 number was 30% above the forecast.The dividend here is also solid. NexPoint started out with a 22-cent per share payment in Q1, and raised it in Q2 to its current level of 40 cents per common share. This annualizes to $1.60, making the yield an impressive ~10%.Stephan Laws, 5-star analyst with Raymond James, is impressed with what he sees here. Laws writes of NexPoint, “Recent investments should drive significant core earnings growth, which is reflected in the increased 4Q guidance range of $0.49-0.53 per share (up from $0.46-0.50 per share). The guidance incorporates the full quarter impact of the new 3Q investments as well as new mezz investments made in October. We are increasing our 4Q and 2021 estimates, and we have increased confidence in our forecast for a 1Q21 dividend increase, which we now forecast at $0.45 per share…”Following these sentiments, Laws puts a Strong Buy rating on NREF. His $18 price target suggest the stock has a 9% upside potential for the year ahead. (To watch Laws’ track record, click here)With 2 recent Buy reviews, the analyst consensus on NREF shares is a Moderate Buy. The stock’s $18 average price target matches Laws’, implying 9% growth. (See NREF stock analysis on TipRanks)To find good ideas for dividend stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • 11 Stocks Turned $10,000 Into $886,343 In 11 Months

    It's been an impressive November for S&P 500 stocks. And the month served up another reminder of the power in picking top stocks.

  • Dow Jones Tumbles Amid Moderna Coronavirus Vaccine Data; Tesla Reverses From Record High, As Nikola Plunges

    The Dow Jones Industrial Average fell more than 350 points amid Moderna coronavirus vaccine news Monday. Tesla jumped to more all-time highs.

  • Moderna Is Firing on All Cylinders; Analyst Boosts Price Target

    At the outset of 2020, Moderna (MRNA) was hardly a household name. But with 2021 in plain sight, the whole world is keeping a close watch on the company’s latest developments.More pointedly, Moderna has firmly planted itself in the general public’s psyche due to its Covid-19 vaccine candidate mRNA-1273. The company reported interim data from a late stage study, in which mRNA-1273 displayed a 94.1% success rate in preventing the coronavirus (100% against severe cases), making the granting of an EUA (emergency use approval) from the FDA increasingly likely. In fact, Brookline Capital analyst Leah Rush Cann believes approval could be sealed by mid-December.After assessing the Moderna model following the vaccine’s positive results, the 5-star analyst noted, “Moderna’s probability of success should be meaningfully increased; therefore, we are lowering our discount and increasing our target price to reflect these changes.”The change is a significant uptick – up from $95 to $164. Unsurprisingly, the analyst’s rating for MRNA stays a Buy. (To watch Cann’s track record, click here)The bullish case for Moderna currently resides with mRNA-1273’s worldwide commercial opportunity. Moderna anticipates manufacturing between 500 million to 1 billion doses next year, and Cann expects the vaccine to account for 99.2% of the company’s 2021 revenue. The US government has already put in an order for 100 million doses of mRNA-1273, with an option to purchase another 400 million. The European Union has ordered 80 million doses and another 56 million are earmarked for Canada.However, Cann also points out the Covid-19 vaccine is just one of several assets in Moderna’s potentially lucrative pipeline.“mRNA-1273 is one of 17 experimental clinical compounds Moderna has in development,” Cann said. “The potential products in clinical development have the potential to have combined estimated sales of $77.1 billion by 2030. In addition, Moderna has seven preclinical programs that have the potential for combined 2030 sales of $8.4 billion.”Most of Cann’s colleagues also look favorably upon Moderna’s prospects, though not all are convinced. Based on 8 Buys, 4 holds and 2 Sells, the stock has a Moderate Buy consensus rating. However, shares have gained 680% year-to-date, and trading at near all-time high of $152.74. The analysts evidently feel the stock has surged enough for now; The $111.46 average price target suggests the share price will drop by 27% over the next 12 months. (See MRNA stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • The 15 worst college majors for making money

    Think carefully about your choice so you can actually pay off your student debt.

  • Zoom Q3 earnings beat analysts' expectations, revenue up 367%

    Zoom beats earnings expectations as the pandemic-driven service continues impressive performance.

  • S&P 500 to swallow Tesla in one gulp; shares surge

    Adding Elon Musk's Tesla to Wall Street's most followed benchmark will force index funds to buy about $73 billion worth of its shares, S&P Dow Jones Indices said. The electric car maker's stock has surged over 40% since Nov. 16, when it was announced Tesla would join the index. At that time, S&P Dow Jones Indices said it would consult investors about whether to potentially add Tesla in two tranches a week apart to make the addition easier to handle for index funds.

  • Dow Jones Futures: Tesla Rallies On S&P 500 Update; Zoom Falls On Earnings; Apple, AMD Lead Stock Market Rally

    The stock market fell Monday but the Nasdaq slashed losses as Apple awoke, Moderna soared and AMD broke out. Zoom Video fell late despite strong earnings. Tesla got an S&P 500 update.

  • Exxon Is Facing Historic Writedown After Energy Markets Implode

    (Bloomberg) -- Exxon Mobil Corp. is about to incur the biggest writedown in its modern history as what was once an exemplar of American capitalist might shudders under the weight of debilitated energy markets.Exxon -- already hobbled by cratering crude prices, a global supply glut and a pandemic-driven collapse in fuel sales -- on Monday disclosed it will write down the value of North and South American natural gas fields by $17 billion to $20 billion. At the top end of that range, it would represent the industry’s steepest impairment since BP Plc’s 2010 Gulf of Mexico oil spill that killed 11 workers and fouled the sea for months. Meanwhile, capital spending will be drastically reduced through 2025.The announcement comes in the waning days of a grueling year for Chief Executive Officer Darren Woods, who’s taken the heretofore anathema steps of firing employees, curtailing retirement benefits and canceling ambitious growth projects. The former refinery manager has been forced to recast his seven-year, $210 billion blueprint for rejuvenating Exxon’s aging portfolio of crude and gas holdings.In addition to dropping vast swaths of gas assets from the development queue, Woods is capping capital spending at $25 billion a year through 2025, a $10 billion reduction from his pre-pandemic target.This year has been particularly bruising for America’s most-iconic oil explorer. Exxon lost money for three consecutive losses, an unprecedented streak, the shares dipped to an 18-year low and the company was ejected from the bosom of blue-chip stocks, the Dow Jones Industrial Average. Woods also plans to cut 15% of the company’s workforce by 15% by the end of next year.From being the largest company in the S&P 500 Index as recently as 2012, Exxon now ranks just inside the top 50 as energy lost its luster and technology giants grew. Chevron Corp. now has a larger market valuation than Exxon.No PivotUnlike its European peers, Exxon has so far chosen to stick with its $15 billion-a-year dividend and has increased borrowing in recent months to fund it and its other capital priorities. On an annualized basis, the dividend has been increased each year for almost four decades.Optimism that vaccines will soon restore global economic growth buoyed crude prices in recent weeks but the impact of the contagion on Big Oil is likely to be longlasting. With European giants Royal Dutch Shell Plc and BP accelerating the pivot to renewables and Exxon locking in drastic spending cuts, capital flows into big, traditional developments are expected to shrink in coming years.Cowen & Co. analyst Jason Gabelman detected a subtle shift in Exxon’s word choices that may herald a dramatic change in financial priorities. Whereas company executives touted Exxon’s “reliable and growing dividend” during the third-quarter earnings conference call, Monday’s statement only mentioned reliability, the analyst said in a note to clients.‘High-Grading’“Continued emphasis on high-grading the asset base -- through exploration, divestment and prioritization of advantaged development opportunities -- will improve earnings power and cash generation, and rebuild balance sheet capacity,” Woods said in the statement.Exxon has been warning shareholders since October that its gas assets were at risk of significant impairment. Previously, the energy titan’s largest writedown was for about $3.4 billion in 2016, according to Bloomberg Intelligence.Assets removed from Exxon’s development plans include so-called dry gas resources in Appalachia and the Rocky Mountains, Oklahoma, Texas, Louisiana and Arkansas, as well as western Canada and Argentina, the company said. It will attempt to sell “less strategic” assets.The writedown stems from former CEO Rex Tillerson’s decision a decade ago to buy XTO Energy for $35 billion rather than spend years building an in-house shale business. At the time, the outlook for North American gas prices was bright because demand was rising faster than supply.Supply GlutInstead, fracking was a victim of its own success, unleashing so much gas that it overwhelmed demand and the infrastructure needed to handle it, resulting in a prolonged stretch of depressed prices.U.S. rival Chevron recorded an impairment of more than $5 billion on Appalachian gas a year ago, and recently agreed to sell those fields to EQT Corp. for about $735 million.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Nikola Scraps Badger Electric Truck After GM Speeds Up EV Plans

    Nikola scrapped plans to build the Badger electric pickup truck in a drastically scaled-down partnership deal with GM.

  • Pot stocks pop ahead of U.S., UN votes on cannabis legalization

    Cannabis stocks continued their postelection rise from the ashes Monday, ahead of votes this week regarding decriminalization in the U.S. House of Representatives and the United Nations.

  • GM will not take a stake in Nikola

    Nikola and GM revise the terms of their previous headline-grabbing deal.

  • Growing Number of Americans Are Facing Early Retirement

    Financial advisors need to help these clients with their retirement planning. A job loss for a person nearing retirement may result in cuts to lifestyle expenses or downsizing the dream for the golden years.

  • If You Left the Market, Don’t Wait to Get Back In

    (Bloomberg Opinion) -- There are only a few basic rules of investing: diversify, keep your costs low and probably most important, hang on when markets tumble occasionally. The last one is the trickiest. It’s not easy watching money vanish as the market plunges, particularly when many people, some of them highly respected, are carping about the end of the world, which invariably accompanies a market collapse.So it was when Covid-19 sent U.S. stocks into a tailspin in late February. The S&P 500 Index shed a third of its value in just more than four weeks, one of the steepest retreats on record, amid widespread chatter that the pandemic would plunge the U.S. into a long depression, wiping out whole industries and permanently damaging broad swaths of the economy.Hanging on to stocks through that chaos was no small feat, and amazingly, most investors managed to do it. Research firm Dalbar, which attempts to track investors’ moves into and out of mutual funds, concluded in a recent report that “the average investor’s appetite for equities has remained unchanged throughout the Covid crisis.” Vanguard Group, which oversees more than $6 trillion in assets, found that less than 0.5% of its retail clients and self-directed investors in its retirement plans panicked and moved to all cash between Feb.19, the market’s pre-coronavirus peak, and May 31.That’s a big change from previous meltdowns, most recently the 2008 financial crisis, when investors dumped stocks in droves. It seems to have finally sunk in that all crises pass and that the stock market eventually recovers, no matter how desperate things seem at the time.  And true to form, the market recovered sooner than anyone expected. It shot higher in late March and surpassed its pre-Covid high in August, even as the coronavirus showed few signs of slowing. As it turned out, the recovery began roughly eight months before news arrived that a highly effective vaccine is in hand and will start to be distributed soon. That sounds about right.    Those who dumped their stocks along the way, gambling that the market is poised for a long slump and would give them an opening to reenter at even lower prices, now face a hard choice. The market is up roughly 60% from its March low, so getting back in means coming to terms with a costly mistake. Say you had $100,000 in the market at the pre-coronavirus peak and sold roughly halfway down, recovering about $83,000. If you had stayed in the market, you would have roughly $107,000 today, or close to 30% more money than when you exited. That’s tough to swallow.But the alternative is worse. The temptation is to wait stubbornly for the market to revisit its lows, a day that may never come. During the financial crisis, the market turned sharply higher in March 2009, even though it was not yet evident that a collapse of the financial system would be averted. When the all-clear came several months later, the market had risen roughly 60% through October.Sound familiar? Investors who dumped their stocks during the financial crisis faced the same choice modern-day deserters do now. Those who jumped back in after the crisis eased in 2009 have more than tripled their money despite buying back at what must have seemed like an outrageous price at the time, while those who waited for the elusive ideal reentry are still waiting.  There are countless other examples. With rare exception, when the market surges from the depths of a crisis, it’s a signal that it has moved on, even if some investors have not. Chances are, the market has moved on from Covid-19, and investors should, too. The next time — and yes, there will be a next time — investors are tempted to dump their stocks during a crisis, they should focus not on getting out but getting back in. That should clarify the wisdom of staying put. No one can anticipate the bottom in advance, which means that the reentry will either be too early or too late. And too early is unrealistic. If you’re tempted to run for the exit when the market is down 20%, you probably won’t be in the mood to buy when it’s down 30% or more. That leaves one alternative: buying late, which is the pickle some investors are in now. It’s best to avoid that quandary altogether by remaining invested.For now, those who got out should recognize that there will never be a better time to get back in, at least one that can be known in advance.This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Nir Kaissar is a Bloomberg Opinion columnist covering the markets. He is the founder of Unison Advisors, an asset management firm. He has worked as a lawyer at Sullivan & Cromwell and a consultant at Ernst & Young. For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Artificial Intelligence Stocks To Buy And Watch Amid Rising AI Competition

    When looking for the best artificial intelligence stocks to buy, identify companies using AI technology to improve products or gain a strategic edge, such as Microsoft, Netflix and Nvidia.

  • Is Novavax Stock A Buy As Pressure Mounts For A Covid-19 Vaccine?

    Novavax is making a play for a coronavirus vaccine, vs. giants like Pfizer, and other rivals like Moderna. But NVAX stock has been volatile. Is Novavax a buy?

  • EV bus and truck maker The Lion Electric to take SPAC route to public markets

    Canadian electric truck and bus manufacturer The Lion Electric Company said Monday it plans to become a publicly traded company via a merger with special purpose acquisition company Northern Genesis Acquisition Corp. The combined company, which will be listed on the New York Stock Exchange, will have a valuation of $1.9 billion. The deal is the latest example of an electric automaker opting to go public via a SPAC merger in an aim to access the level of capital needed to become a high-volume vehicle manufacturer.

  • Five Energy Stocks To Buy Before Christmas

    The year is coming to an end, and bullish news is mounting for the energy industry, presenting an array of juicy deals to watch this holiday season

  • Tesla S&P Debut to Come All at Once, Rippling Across Markets

    (Bloomberg) -- Tesla Inc. will be added to the S&P 500 Index in one shot on Dec. 21, a move that will ripple through the entire market as money managers adjust their portfolios to make room for shares of the $538 billion company.Given Tesla’s massive market size, S&P had sought a consultation with investors earlier in November, asking for feedback on whether the stock should be folded into the index all at once or in two parts, which would have been unprecedented. The electric-vehicle maker will be the seventh-biggest company in the S&P 500 at its current market value, falling between Berkshire Hathaway Inc. and Visa Inc.With about $11 trillion in funds tied to the S&P 500, money managers have been looking toward a few busy weeks ahead no matter how Tesla was included in the index. Whether it was one fell swoop or two separate tranches, managers of index-tracking funds would still have had to offload stocks of several other companies to make room for the mammoth newcomer in their portfolios.“It looks like they’re ripping the band-aid off,” said Steve Sosnick, chief strategist at Interactive Brokers. “It’s ultimately less disruptive than trying something new with the largest index addition ever.”Tesla shares rose more than 4% in postmarket trading after S&P Dow Jones Indices announced the plan in a brief statement on Monday. The index provider said it will release a full statement on Tuesday morning. The stock slipped 3.1% in Monday’s regular session from a record high on Nov. 27. Tesla shares are up about 580% this year.Adding the company in the traditional way is “simple and easy to understand” said Gary Black, a private investor who was chief executive of Aegon Asset Management from mid-2016 through September.After the initial buying into the Dec. 21 inclusion, the stock may pull back, if history is any guide, according to Black. The shares may fall about 10% to 20%, a pattern that would be consistent with what happened to Facebook after its entry into the S&P 500 seven years ago.Read more: Tesla FOMO Fires Up Wall Street’s $300 Billion Custom-Index BoomTesla’s market capitalization is larger than any other company had at its debut in the S&P 500. Berkshire Hathaway previously held that record. It was worth about $127 billion when it was included in the index in 2010.(Adds S&P Dow Jones statement details in fifth paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.